SPC
TXMD icon

Sigma Planning Corp’s TherapeuticsMD TXMD Stock Holding History

Sigma Planning Corp’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-258
Closed -$31K – 1101
2019
Q4 		$31K Buy
258
+26
+11% +$3.74K ﹤0.01% 1039
2019
Q3 		$42K Buy
+232
New +$32.7K ﹤0.01% 985

Other funds holding TXMD

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sigma Planning Corp's TXMD Position: Q1 2020 in Review

Sigma Planning Corp sold out of TherapeuticsMD (TXMD) in Q1 2020, closing a stake of 258 shares — an estimated $31K sold.

Sigma Planning Corp first reported a position in TXMD in Q3 2019 and held it in 2 quarters. The position peaked at $42K in Q3 2019. 143 funds tracked by Wall St. Rank hold TXMD as of Q1 2020.

  • Sigma Planning Corp reported no remaining TherapeuticsMD position as of Q1 2020 after selling out during the quarter.
  • Sigma Planning Corp sold 258 TherapeuticsMD shares in Q1 2020, an estimated $31K.
  • Sigma Planning Corp first reported a position in TherapeuticsMD in Q3 2019 and held it in 2 quarters.
  • Sigma Planning Corp's TherapeuticsMD position peaked at $42K in Q3 2019.
  • 143 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2020.

Based on Sigma Planning Corp's 13F filing for Q1 2020, filed 1 May 2020.